Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 78.06M P/E - EPS this Y 62.80% Ern Qtrly Grth -
Income -131.56M Forward P/E -0.79 EPS next Y -29.60% 50D Avg Chg 11.00%
Sales 4.15M PEG - EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 0.72 EPS next 5Y - 52W High Chg -66.00%
Recommedations 2.00 Quick Ratio 3.22 Shares Outstanding 26.81M 52W Low Chg 57.00%
Insider Own 1.32% ROA -51.11% Shares Float 13.94M Beta 1.58
Inst Own 81.10% ROE -393.39% Shares Shorted/Prior 1.10M/1.24M Price 3.79
Gross Margin - Profit Margin - Avg. Volume 74,632 Target Price 11.00
Oper. Margin -2,835.00% Earnings Date Nov 12 Volume 39,194 Change -3.81%
About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Syros Pharmaceuticals, Inc. News
11/14/24 Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
11/14/24 Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
11/13/24 Syros stock craters after lead cancer therapy flops in Phase III trial
11/12/24 Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
11/02/24 Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)
11/01/24 Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...
10/31/24 Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
10/24/24 Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
10/09/24 Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...
09/14/24 Insider Spends US$161k Buying More Shares In Syros Pharmaceuticals
09/12/24 Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)
09/12/24 Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)
08/27/24 Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
08/14/24 Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
08/14/24 Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
08/13/24 Top Midday Decliners
08/13/24 Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
08/13/24 Syros’ stock craters after Phase II AML trial termination due to inefficacy
08/12/24 Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
08/05/24 Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
SYRS Chatroom

User Image ICEMAN_kkb Posted - 57 minutes from now

$SYRS sentiment bullish now? 🤔

User Image Denaciousrajan Posted - 20 minutes from now

$SYRS cmon

User Image Arabella72 Posted - 21 minutes ago

$SYRS was the average price raised from 8.50 to 10.50

User Image DharlMorey2 Posted - 58 minutes ago

$ATOS 'anti-cancer' activity. Atossa will be the leader in preventing and curing Breast Cancer. Two simultaneous conference presentations (AACR and SABCS) now. AACR Dec. 9, and most presentations for SABCS around the 10/11th of December for presentations. https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-present-poster-z-endoxifen-aacr-special $XBI $DRUG $AMAM $SYRS

User Image Denaciousrajan Posted - 1 hour ago

$SYRS I might dip this mat be it.

User Image LittleIronman2 Posted - 1 hour ago

$SYRS decided to bail with those insiders selling. Maybe they are just the worlds worst traders and we should do opposite 🤷🏼‍♂️.

User Image Denaciousrajan Posted - 1 hour ago

$SYRS low volume got me nervous

User Image sonicstriker Posted - 1 hour ago

$SYRS is firing staff and selling shares, it could signal a strategic pivot or a move to streamline operations for a leaner, more focused business model. While these actions might seem bearish on the surface, they could position the company for a potential turnaround, partnership, or acquisition. Market overreactions often create opportunities for those who can see the long-term vision.

User Image spirit88 Posted - 2 hours ago

$SYRS over .32 cents today

User Image Harunkaraca Posted - 2 hours ago

$SYRS

User Image Denaciousrajan Posted - 3 hours ago

$SYRS I feel like I’m the only one posting. Is the hype gone?

User Image Denaciousrajan Posted - 5 hours ago

$SYRS the insider sale of shares is surely an indicator to get out, is it? I lost a lot with SAVE and would like to avoid a repeat.

User Image lucabrix Posted - 6 hours ago

$SYRS Insiders must be real beggars: they sell shares for 7k and 2K dollars! Starving!!!

User Image Denaciousrajan Posted - 6 hours ago

$SYRS need a boost

User Image Harunkaraca Posted - 7 hours ago

$SYRS let s gooo guyzzz

User Image dkc1223 Posted - 15 hours ago

$SAVA two execs at $SYRS purchased 100k shares each two months before their p3 readout. Last week, they reported the figures and informed the investors that they will terminate their research. Stock dropped over 95% from $3 to $0.16. New hires, option grants, really don’t mean much. They’ll get your money one way or another. Rely on facts. Only facts.

User Image spirit88 Posted - 15 hours ago

$SYRS up up

User Image Resuhai Posted - 15 hours ago

$SYRS 🤔

User Image Harunkaraca Posted - 17 hours ago

$SYRS ah fuckery with 80 k volume😀

User Image spirit88 Posted - 18 hours ago

$SYRS closing green

User Image lucabrix Posted - 19 hours ago

$SYRS nice final paw, two days green is reversal!

User Image spirit88 Posted - 20 hours ago

$SYRS up up

User Image Harunkaraca Posted - 20 hours ago

$SYRS who is selling? Let it fly mfkers😂

User Image LittleIronman2 Posted - 20 hours ago

$SYRS ☝️

User Image alecsalaur198 Posted - 21 hours ago

$SYRS let s go 0.5$

User Image RETAlerts Posted - 21 hours ago

omentum is building for $SYRS at 0.299, now up 10% since our first mention. Keep an eye on the moving averages for potential support levels during any pullbacks. (15 minute delay)

User Image spirit88 Posted - 21 hours ago

$SYRS .40 back

User Image taneraydar Posted - 21 hours ago

$SYRS .44 incoming

User Image Wtfyw76 Posted - 21 hours ago

$SYRS 💰🥳

User Image spirit88 Posted - 21 hours ago

$SYRS added going to .40

Analyst Ratings
Piper Sandler Overweight Aug 13, 24
JMP Securities Market Outperform Aug 13, 24
HC Wainwright & Co. Buy Aug 13, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy Jun 26, 24
HC Wainwright & Co. Buy May 15, 24
Piper Sandler Overweight Apr 3, 24
HC Wainwright & Co. Buy Apr 1, 24
Piper Sandler Overweight Oct 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
AKKARAJU SRINIVAS Director Director Dec 21 Buy 4.42 904,977 3,999,998 1,786,427 12/26/23
Olson Eric R Chief Scientific Off.. Chief Scientific Officer Jul 17 Sell 3.50 689 2,412 6,661 07/18/23
Young Richard A Director Director Feb 10 Sell 8.87 5,990 53,131 329,211 02/10/21
Simonian Nancy A President & CEO President & CEO Dec 21 Option 7.21 29,917 215,702 563,606 12/21/20
Young Richard A Director Director Nov 18 Sell 8.87 5,990 53,131 339,211 11/18/20